- Home
- KALU vs MYGN Comparison
KALU vs MYGN Comparison
Compare KALU & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALU
- MYGN
- Stock Information
- Founded
- KALU 1946
- MYGN 1991
- Country
- KALU United States
- MYGN United States
- Employees
- KALU N/A
- MYGN N/A
- Industry
- KALU Metal Fabrications
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- KALU Industrials
- MYGN Health Care
- Exchange
- KALU Nasdaq
- MYGN Nasdaq
- Market Cap
- KALU 1.1B
- MYGN 1.2B
- IPO Year
- KALU 1991
- MYGN 1995
- Fundamental
- Price
- KALU $71.86
- MYGN $14.18
- Analyst Decision
- KALU Buy
- MYGN Hold
- Analyst Count
- KALU 2
- MYGN 13
- Target Price
- KALU $90.00
- MYGN $22.54
- AVG Volume (30 Days)
- KALU 98.0K
- MYGN 1.2M
- Earning Date
- KALU 02-19-2025
- MYGN 02-24-2025
- Dividend Yield
- KALU 4.24%
- MYGN N/A
- EPS Growth
- KALU N/A
- MYGN N/A
- EPS
- KALU 2.87
- MYGN N/A
- Revenue
- KALU $3,024,000,000.00
- MYGN $823,600,000.00
- Revenue This Year
- KALU N/A
- MYGN $13.60
- Revenue Next Year
- KALU $4.72
- MYGN $3.25
- P/E Ratio
- KALU $25.34
- MYGN N/A
- Revenue Growth
- KALU N/A
- MYGN 12.15
- 52 Week Low
- KALU $63.44
- MYGN $12.04
- 52 Week High
- KALU $102.42
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- KALU 49.76
- MYGN 55.82
- Support Level
- KALU $69.59
- MYGN $14.13
- Resistance Level
- KALU $77.11
- MYGN $15.47
- Average True Range (ATR)
- KALU 2.40
- MYGN 0.72
- MACD
- KALU 0.27
- MYGN 0.27
- Stochastic Oscillator
- KALU 40.61
- MYGN 61.38
About KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from United States.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.